What's in Global Alliance for TB Drug Development's pipeline?

Global Alliance for TB Drug Development has 14 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 7 in Phase 1.

Which companies overlap with Global Alliance for TB Drug Development's portfolio?

Top competitors by shared drug class: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Allergan, Bayer, Bayer AG, Carolina Eyecare Physicians, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/global-alliance-for-tb-drug-development.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Global Alliance for TB Drug Development — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Global Alliance for TB Drug Development pipeline: 2 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 2 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
HR	HR	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)	Infectious Disease
Moxifloxacin (M)	Moxifloxacin (M)	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV	Infectious Disease
HRZE	HRZE	phase 3	Fixed-dose combination antituberculous agent	Multiple: KatG/InhA (isoniazid), bacterial RNA polymerase (rifampicin), PncA/RpoB (pyrazinamide), arabinosyl transferase (ethambutol)	Infectious Disease
Pyrazinamide (Z)	Pyrazinamide (Z)	phase 3	Nicotinamide analog; antituberculous agent	Pantothenate synthetase (PanC); pyrazinamidase activation	Infectious Disease
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin	Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin	phase 3	Anti-tuberculosis agent combination	Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol)	Infectious Disease

Therapeutic area mix

Infectious Disease · 5
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Allergan · 1 shared drug class
Bayer · 1 shared drug class
Bayer AG · 1 shared drug class
Carolina Eyecare Physicians, LLC · 1 shared drug class
Connect Biopharma Australia Pty Ltd · 1 shared drug class
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Global Alliance for TB Drug Development:

Cite this brief

Drug Landscape (2026). Global Alliance for TB Drug Development — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/global-alliance-for-tb-drug-development. Accessed 2026-05-16.